View : 525 Download: 0
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society
- Title
- Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society
- Authors
- Kang Y.-J.; Oh S.J.; Choi H.; Cho S.; Shin C.-H.; Kim C.; Woo J.; Lee J.S.; Park H.K.; Lee H.-B.; Noh W.C.; Kim Y.-S.
- Ewha Authors
- 우주현
- SCOPUS Author ID
- 우주현
- Issue Date
- 2021
- Journal Title
- Breast Cancer Research and Treatment
- ISSN
- 0167-6806
- Citation
- Breast Cancer Research and Treatment vol. 186, no. 1, pp. 125 - 134
- Keywords
- Breast cancer; ERBB-2; Human epidermal growth factor receptor 2; Intrinsic factor; Trastuzumab
- Publisher
- Springer
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Purpose: The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials. The objective of this study was to evaluate the survival of patients in a monoethnic group diagnosed with T1b lymph node-negative breast cancer depending on HER2 status. Methods: We analyzed 3110 patients with T1bN0M0 breast cancer whose data were deposited into the Korean Breast Cancer Society Registry database between 2000 and 2009. Overall survival (OS) and breast cancer-specific survival (BCSS) were compared according to HER2 status. Results: Among all patients, 494 (15.9%) had HER2-positive breast cancer. At a mean follow-up of 93 months, 108 deaths and 86 breast cancer-specific deaths were noted among all patients. There was no significant difference in OS between the HER2-negative and HER2-positive groups (p = 0.103). The same result was observed for BCSS. However, in the subgroup of estrogen receptor (ER)-positive women, HER2-negative patients had a better BCSS prognosis than HER2-positive patients (p = 0.025). Multivariate analysis also indicated a significant difference in BCSS in the ER-positive subgroup (HR 2.60; 95% CI 1.15–5.87; p = 0.021). Conclusion: This study analyzed a large nationwide and monoethnic cohort and found a significant difference only in BCSS in the ER-positive subgroup according to HER2 status. Anti-HER2 therapy may be considered in HER2-positive and ER-positive patients with small, node-negative breast cancer. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
- DOI
- 10.1007/s10549-020-06017-2
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML